HPGC Renmintongtai Pharmaceutical Corporation (600829) Fair Value & Analysis
Healthcare · CN · Market cap 4.9B CNY
Analysis
HPGC Renmintongtai Pharmaceutical Corporation (600829) currently trades at ¥8.12, while our model-based Fair Value estimate is ¥6.91 — implying the stock looks roughly 14.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosmetics products. It also provides logistics services, including warehousing and distribution services; and hospital services comprising medical treatment, scientific research, prevention, health care, rehabilitation, and hemodialysis and kidney disease treatment. Further, it is involved in distribution of medical equipment and operation of Chinese medicine and outpatient clinics. It serves its products through e-commerce platform, a chain of direct stores and online B2C, O2O, etc. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporat…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.